ClinicaliQ Trial Snapshot
- An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) — Active Not Recruiting • Phase II / Phase III….
- Diacerein ointment tested for safety and effectiveness in treating generalized epidermolysis bullosa simplex blistering disorder.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS. Conditions: Generalized Epidermolysis Bullosa Simplex Interventions: AC-203, Vehicle Lead Sponsor: TWi Biotechnology, Inc. Planned Enrollment: 80 participants